Pharmaceutical company Mayne Pharma
(ASX:MYX) reported a full-year net loss of $280.8 million down 110 per cent on last year's $133.9 million loss impacted by intangible asset impairments.
Revenues of $525.2 million, down 1 per cent on the prior corresponding period (pcp).
They posted a non-cash impairment charge of $351.7 million.
The company launched two specialty brand products in the US, TOLSURA® capsule and LEXETTE™ (halobetasol) foam and five generic products, they are expecting a stronger financial year 2020 driven by these.
Shares in Mayne Pharma
(ASX:MYX) are down 1.1 per cent to 47 cents.
